Back to Authors

Ahsan, Sama

A5110854696 | I1285764155

Mayo Clinic

Merck & Co., Inc., Rahway, NJ, USA (United States)

Citations 1

5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 9516-9516

10.1200/jco.2018.36.15_suppl.9516